Ginkgo Bioworks Holdings Inc vs Consolidated Edison, Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.75 (market cap $763.64M), while Consolidated Edison, Inc. trades at $105.97 (market cap $39.20B). The key difference: Consolidated Edison, Inc. is far larger — about 51.3× Ginkgo Bioworks Holdings Inc's market cap, and Consolidated Edison, Inc. pays a 3.31% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Consolidated Edison, Inc. for 75 Days on average.
| DNA | ED | |
|---|---|---|
Market Cap | $763.64M | $39.20B |
Volume | 3,204,177 | 2,142,900 |
Sector | Health | Utilities |
52-Week High | $15.83 | $115.46 |
52-Week Low | $5.48 | $95.37 |
Typical Hold Time | 7 Days | 75 Days |
Enterprise Value | $865.59M | $66.05B |
Dividend Yield | — | 3.31% |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.
Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.
Consolidated Edison (ED) trades at $104.65, down 0.45% on the day, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The company maintains solid fundamentals with a P/E of 17.43, net income margin of 12.53%, and a $0.89 dividend. Revenue grew to $16.92B in 2025, with cash flow from operations strong at $4.80B. Analyst consensus is a Hold with a $106.33 price target, slightly above the current price.
ED's outlook is stable, supported by its utility business model and dividend aristocrat status, but faces risks from high debt levels and interest expenses. The stock offers income appeal with moderate growth potential, though investor sentiment is cautious amid mixed analyst ratings and institutional selling trends noted in recent filings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →